MAIA Biotechnology grants 29,789 stock options to company director

MAIA Biotechnology, Inc. reported that director Louie Ngar Yee received a grant of stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan.

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. reported that director Louie Ngar Yee received a grant of stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan. The grant covers 29,789 options to buy common stock at an exercise price of $1.53 per share.

The options vest 100% on the grant date and are exercisable beginning 12/31/2025, giving the director the right to purchase MAIA common shares at this fixed price. These options expire on 12/31/2035 if not exercised, so they represent a long-term equity incentive tied to the company’s future performance.

Insider Trade Summary

Grant/Award: 29,789 shares

Grant/Award 1 txn

Insider Louie Ngar Yee

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Options	29,789	$0.00	$0.00

Holdings After Transaction: Options — 29,789 contracts (Direct)

Footnotes (1)

1. F1. The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

FAQ

What insider transaction did MAIA (MAIA) report in this Form 4?

MAIA Biotechnology, Inc. reported a stock option grant to director Louie Ngar Yee covering 29,789 options to purchase common stock.

What is the exercise price of the MAIA stock options granted to the director?

The stock options have an exercise price of $1.53 per share for MAIA Biotechnology, Inc. common stock.

When did the MAIA director stock options vest and become exercisable?

The options were granted on 12/31/2025, vest 100% on the grant date, and are exercisable beginning as of that same date.

When do the MAIA Biotechnology director stock options expire?

The stock options granted to the director expire on 12/31/2035 if they are not exercised by that date.

Under which plan were the MAIA director’s stock options granted?

The options were granted pursuant to MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan.

What type of security underlies the MAIA director’s options and how many shares are covered?

The options are exercisable for 29,789 shares of common stock of MAIA Biotechnology, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/05/2026 - 08:39 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Louie Ngar Yee

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	$1.53	12/31/2025		A		29,789		12/31/2025(1)	12/31/2035	Common Stock	29,789	$0	29,789	D

Explanation of Responses:

1. The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Louie Ngar Yee	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.